United-Guardian, Inc. (UG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

United-Guardian, Inc. (UG) Consumer Business Overview

United-Guardian, Inc. (UG) is a manufacturer of specialty products including cosmetic ingredients like LUBRAJEL, pharmaceuticals such as RENACIDIN, medical lubricants, and industrial solutions. With a global presence and a focus on proprietary formulations, UG serves niche markets within the consumer defensive sector, supported by a 7.28% dividend yield.

What Is the Investment Thesis for UG?

With a P/E ratio of 13.31 and a profit margin of 21.6%, the company demonstrates financial stability. The dividend yield of 7.28% offers an attractive income stream for investors. Growth catalysts include expanding the applications of its LUBRAJEL line and increasing market penetration for RENACIDIN and CLORPACTIN WCS-90. Key risks include reliance on a limited number of products and vulnerability to competition from larger players in the cosmetic ingredients and pharmaceutical sectors. The company's small market capitalization of $32.7M may limit liquidity.

Based on FMP financials and quantitative analysis

UG Key Highlights

Market capitalization of $32.7M indicates a small-cap company with potential for growth.

• P/E ratio of 13.31 suggests the company may be undervalued compared to its earnings.
• Profit margin of 21.6% demonstrates strong profitability and efficient operations.
• Gross margin of 46.6% highlights the company's ability to maintain a healthy profit on its sales.
• Dividend yield of 7.28% provides a significant income stream for investors.

Who Are UG's Competitors?

UG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are UG's Key Strengths?

Proprietary product formulations (e.g., LUBRAJEL)

• Established presence in niche markets
• Consistent profitability
• High dividend yield

What Are UG's Weaknesses?

Small market capitalization

• Limited product diversification
• Reliance on a small number of employees
• Limited marketing resources

What Could Drive UG Stock Higher?

Potential for new product approvals for pharmaceutical products.

• Expansion of the LUBRAJEL product line into new applications.
• Increased marketing efforts to drive sales growth in existing markets.

What Are the Key Risks for UG?

Competition from larger companies with greater resources.

• Changes in regulatory requirements affecting the pharmaceutical and cosmetic industries.
• Economic downturns reducing demand for discretionary consumer products.
• Reliance on a small number of key employees.

What Are the Growth Opportunities for UG?

• Expansion of LUBRAJEL Product Line: United-Guardian can expand the LUBRAJEL product line into new cosmetic and personal care applications. The global market for cosmetic ingredients is estimated to reach $40 billion by 2027. By developing new LUBRAJEL formulations tailored to specific skin types and cosmetic products, United-Guardian can capture a larger share of this market. Timeline: Ongoing.
• Increased Market Penetration for RENACIDIN: United-Guardian can increase the market penetration of RENACIDIN, its prescription drug for urinary calcifications. The market for urological drugs is growing due to the aging population and increasing prevalence of urinary disorders. By expanding its marketing efforts and distribution network, United-Guardian can reach more patients and healthcare providers. Timeline: Ongoing.
• Development of New Pharmaceutical Products: United-Guardian can invest in research and development to develop new pharmaceutical products targeting unmet medical needs. The global pharmaceutical market is a multi-billion dollar industry, with significant opportunities for innovative treatments. By leveraging its expertise in drug formulation and regulatory affairs, United-Guardian can create new revenue streams. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: United-Guardian can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other companies in the cosmetic ingredients and pharmaceutical sectors can provide access to new technologies, distribution channels, and customer bases. Timeline: Ongoing.
• International Expansion: United-Guardian can expand its international presence by entering new markets and establishing local distribution partnerships. The global market for cosmetic ingredients and pharmaceuticals is growing rapidly in emerging economies. By adapting its products to local preferences and regulatory requirements, United-Guardian can tap into these new growth opportunities. Timeline: Ongoing.

What Are UG's Competitive Advantages?

• Proprietary Formulations: United-Guardian's proprietary formulations, such as the LUBRAJEL line, provide a competitive advantage due to their unique properties and performance.
• Niche Market Focus: The company's focus on niche markets allows it to cater to specific customer needs and avoid direct competition with larger players.
• Established Customer Relationships: United-Guardian has established long-term relationships with its customers, providing a stable source of revenue.
• Regulatory Expertise: The company's expertise in regulatory affairs, particularly in the pharmaceutical sector, provides a barrier to entry for potential competitors.

What Does UG Do?

Founded in 1942 and headquartered in Hauppauge, New York, United-Guardian, Inc. has established itself as a manufacturer and marketer of a diverse range of specialty products. These include cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary industrial products. The company's cosmetic ingredient offerings feature the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, including variations like LUBRAJEL NATURAL, LUBRAJEL MARINE, LUBRASIL II SB, LUBRAJEL II XD, B-122, KLENSOFT, and ORCHID COMPLEX. These ingredients cater to various cosmetic applications, from pressed powders to skin creams. United-Guardian's medical lubricant products include LUBRAJEL RR, RC, MG, LC, FA, and FLUID, designed for applications such as urinary catheters and oral care. The pharmaceutical segment includes RENACIDIN, a prescription drug for urinary calcifications, and CLORPACTIN WCS-90, an antimicrobial product. Industrial products consist of DESELEX, a sequestering agent, and THOROCLENS, an industrial cleanser. United-Guardian markets its products through a network of marketing partners, distributors, and wholesalers, operating both in the United States and internationally.

What Products and Services Does UG Offer?

• Manufactures and markets cosmetic ingredients for various applications.
• Produces medical lubricants for use in medical procedures and devices.
• Develops and sells pharmaceutical products, including prescription drugs.
• Offers specialty industrial products, such as detergents and cleansers.
• Conducts research and development to create new and improved products.
• Markets products through marketing partners, distributors, and wholesalers, both domestically and internationally.

How Does UG Make Money?

• Develops and manufactures proprietary formulations for cosmetic, pharmaceutical, medical, and industrial applications.
• Markets and sells these products through a network of distributors, wholesalers, and marketing partners.
• Generates revenue from the sale of its products to end-users in various industries.
• Invests in research and development to create new products and improve existing ones.

What Industry Does UG Operate In?

United-Guardian operates within the consumer defensive sector, specifically in the household and personal products industry. This sector is generally stable, as demand for essential goods remains consistent regardless of economic conditions. The market for cosmetic ingredients and specialty pharmaceuticals is competitive, with larger companies often dominating. United-Guardian differentiates itself through its proprietary formulations and focus on niche applications. The company's success depends on its ability to innovate and maintain its competitive edge in these specialized markets.

Who Are UG's Key Customers?

• Cosmetic manufacturers who use United-Guardian's ingredients in their products.
• Healthcare providers who use United-Guardian's medical lubricants and pharmaceuticals.
• Industrial companies that use United-Guardian's specialty industrial products.
• Distributors and wholesalers who resell United-Guardian's products to end-users.

Company Profile

United-Guardian, Inc. operates in the Household & Personal Products industry within the Consumer Defensive sector. It is headquartered in Hauppauge, US. The company is led by CEO Donna Vigilante. UG has traded publicly since 1980.

United-Guardian, Inc. Financial Trajectory

United-Guardian, Inc. (UG) reported $3.1M in revenue for Q2 FY2026, reflecting 8.2% growth compared to the prior quarter. The company recorded net income of $729K, with diluted EPS of $0.16. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Consumer Defensive. Across the four most recent quarters, UG averaged $0.13 in diluted EPS.

How United-Guardian, Inc. Is Valued

United-Guardian, Inc. carries a market capitalization of $32.7M, placing it in the micro-cap category. Relative to its peer group, UG's quantitative score of 77/100 is above the peer average of 43/100.

Return on equity for United-Guardian, Inc. stands at 22.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 18.1%, showing how much profit it generates from its asset base. UG trades at a trailing price-to-earnings ratio of 13.31, below the Consumer Defensive sector average of ~27.60x. Its free cash flow yield is 10.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.6%, the inverse of the P/E and a quick read on earnings relative to price.

United-Guardian, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.58 places it in the safe zone, indicating low near-term bankruptcy risk.

The most recent 9 insider filings for United-Guardian, Inc. break down as 9 sales and 0 purchases. On net that is roughly 49K shares disposed (about $0), a signal worth weighing alongside the fundamentals.

UG Financials

UG Latest News

UG Analyst Consensus

UG MoonshotScore

Common Questions About UG (Consumer Defensive)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources